Yan Xu, Lee Shiowjen, Li Ning
U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
J Biopharm Stat. 2009 Nov;19(6):1085-98. doi: 10.1080/10543400903243009.
One of the major problems in the analysis of clinical trials is missing data caused by patients dropping out before study completion. The issue of missing data can result in biased treatment comparisons and can impact the interpretation of study results. Since the missing data mechanism is unknown and unverifiable in most situations, regulatory agencies often request various sensitivity analyses for handling missing data to evaluate the robustness of study results. This article discusses methods used to handle missing data in medical device clinical trials, focusing on tipping-point analysis as a general approach for the assessment of missing data impact. Tipping points are outcomes that result in a change of study conclusion. Such outcomes can be conveyed to clinical reviewers to determine if they are implausibly unfavorable. The analysis aids clinical reviewers in making judgment regarding treatment effect in the study. Three examples with a reasonably representative range of missing data rate are included to illustrate the methods referred.
临床试验分析中的一个主要问题是,患者在研究完成前退出导致数据缺失。数据缺失问题可能导致治疗比较出现偏差,并可能影响对研究结果的解读。由于在大多数情况下,数据缺失机制是未知且无法验证的,监管机构通常要求进行各种敏感性分析来处理数据缺失问题,以评估研究结果的稳健性。本文讨论了医疗器械临床试验中处理数据缺失的方法,重点介绍了临界点分析这一评估数据缺失影响的通用方法。临界点是导致研究结论改变的结果。这些结果可传达给临床审评人员,以确定它们是否极不合理地不利。该分析有助于临床审评人员对研究中的治疗效果做出判断。文中包含三个具有合理代表性的数据缺失率范围的例子,以说明所提及的方法。